EWTX
Edgewise Therapeutics, Inc. $40.30 -2.66% 2026-10-05 종가 기준핵심 지표
yfinance 기준분기 실적
매출·순이익 · yfinance연간 실적 5년
SEC 10-K · 회계연도 · 달러잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
잉여현금흐름 $-0.0B
EPS 서프라이즈
최근 4분기 · 실제 vs 예상수익성·성장
최근 12개월 기준사업 개요
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.